Welcome to our dedicated page for Bio-Rad Laboratories news (Ticker: BIO), a resource for investors and traders seeking the latest updates and insights on Bio-Rad Laboratories stock.
Bio-Rad Laboratories, Inc. (NYSE: BIO) is a global leader in providing innovative tools and services to the life science research and clinical diagnostics markets. Established in 1952 and headquartered in Hercules, California, Bio-Rad boasts a robust network of operations spanning the globe, supported by a dedicated team of over 7,600 employees.
Bio-Rad's core business is segmented into two main areas: Clinical Diagnostics and Life Sciences. In the Clinical Diagnostics segment, which contributes to 56% of the company’s sales, Bio-Rad offers a range of test systems and specialized quality controls designed to ensure the accuracy and reliability of clinical laboratory results. These products play a critical role in patient care, enabling healthcare providers to make informed decisions.
The Life Sciences segment, accounting for 44% of sales, focuses on developing and manufacturing instruments and reagents used in research, biopharmaceutical production, and food testing. Bio-Rad is also a market leader in digital PCR (dPCR) technology, which is pivotal in genomics, proteomics, and drug discovery research.
Bio-Rad serves over 100,000 research and industry customers worldwide, fostering significant advancements in scientific research and development. The company has built strong partnerships and customer relationships that drive the introduction of new technologies in fields such as genomics, proteomics, drug discovery, food safety, and medical diagnostics.
Geographically, Bio-Rad's revenue distribution is diversified with 42% of sales from the Americas, 31% from Europe, 31% from Asia, and 6% from other regions, highlighting its extensive global reach.
One notable aspect of Bio-Rad's portfolio is its 33% ownership in Sartorius, a leading supplier of laboratory and bioprocessing solutions. Sartorius specializes in single-use technology for biologics manufacturing, thereby complementing Bio-Rad's offerings and enhancing its presence in the biopharmaceutical market.
With a strong legacy of innovation and a commitment to advancing scientific and medical research, Bio-Rad continues to lead in delivering high-quality, reliable solutions to its customers.
Bio-Rad Laboratories (NYSE: BIO and BIOb) announced a final settlement with 10x Genomics (Nasdaq: TXG) to resolve multiple litigations across various regions, including Massachusetts and Germany. This settlement includes a global patent cross-license, granting Bio-Rad broad freedom-to-operate in the single-cell genomics market, along with past and future royalties. Both companies maintain their patent rights, affirming their validity. The CEO of Bio-Rad expressed satisfaction over the resolution, highlighting the value of the company's intellectual property rights.
Bio-Rad Laboratories (NYSE: BIO, BIOb) will announce its Q2 2021 financial results on July 29, 2021, after market close. The results will be discussed in a conference call at 3 PM PT (6 PM ET). Investors can listen in by calling 855-779-9068 in the U.S. or 631-485-4862 internationally, with a passcode of 5382265. A webcast will also be available on the company’s website under “Quarterly Results” and will remain accessible for one year. Bio-Rad, based in Hercules, California, reported revenues of over $2.5 billion in 2020.
Bio-Rad Laboratories (NYSE: BIO, BIOb) has partnered with Seegene, Inc. to develop and commercialize infectious disease molecular diagnostic products. Seegene will supply diagnostic tests for Bio-Rad's CFX96™ Dx Real-Time PCR System, pending FDA clearance. The partnership aims to enhance diagnostic testing in U.S. markets. Seegene's assays are noted for their multiplex capabilities, detecting up to seven infectious disease targets simultaneously with results available in about four hours. This collaboration aligns with Bio-Rad's mission to improve healthcare through innovative diagnostic solutions.
Bio-Rad Laboratories (NYSE: BIO, BIOb) launched the PREvalence™ ddPCR® SARS-CoV-2 Wastewater Quantification Kit, designed to accurately detect SARS-CoV-2 in wastewater, offering a cost-effective early warning system for communities. This kit can identify the virus days to weeks before individual testing, aligning with CDC recommendations. It integrates with Bio-Rad’s existing platforms, enhancing their COVID-19 product portfolio. Bio-Rad emphasizes its commitment to supporting public health amid the ongoing pandemic.
Bio-Rad Laboratories (NYSE: BIO, BIOb) announced that key executives, including President and CEO Norman Schwartz, will participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference on June 2 at noon PT. The event will provide insights into the company's strategies and initiatives. A live webcast link will be available on their Investor Relations page.
Bio-Rad Laboratories reported Q1 2021 net sales of $726.8 million, a 27.1% increase from $571.6 million in Q1 2020. Life Science segment sales rose 61.3% to $366.5 million, driven by COVID-19 product demand. Clinical Diagnostics segment sales increased 5.4% to $358.5 million. Net income surged to $977.4 million ($32.38 per share) from $685.9 million ($22.72 per share) in the previous year. The company expects 5.5% to 6.0% currency-neutral revenue growth for the year. Gross margin slightly declined to 55.1% from 55.5%.
Bio-Rad Laboratories, Inc. (NYSE: BIO, BIOb) will announce its financial results for the first quarter of 2021 on April 29, 2021, after market close. A conference call to discuss these results is scheduled for 3 PM PT (6 PM ET). Investors can participate by calling 855-779-9068 in the U.S. or 631-485-4862 internationally, using the passcode 4692298. Additionally, the call will be available live via a webcast on the company's website.
Bio-Rad Laboratories (NYSE: BIO, BIOb) will participate in a virtual Fireside Chat at the Barclays Global Healthcare Conference on March 9 at 10:15 AM PST. Norman Schwartz (President and CEO), Andrew Last (Executive VP and COO), and Ilan Daskal (Executive VP and CFO) will represent the company. A live webcast will be accessible on their Investor Relations page at bio-rad.com.
Founded in 1952, Bio-Rad is a leader in life science research and clinical diagnostics, boasting over $2.5 billion in revenue in 2020 and 7,800 employees globally.
Bio-Rad Laboratories (NYSE: BIO, BIOb) will have its leadership team, including CEO Norman Schwartz, COO Andrew Last, and CFO Ilan Daskal, participate in a virtual Fireside Chat at Citi's 2021 Healthcare Services conference on February 24 at 11:25 AM PST. This event highlights Bio-Rad's commitment to innovation in life science research and clinical diagnostics. With over 65 years of experience and revenues surpassing $2.5 billion in 2020, Bio-Rad continues to advance healthcare solutions globally.
Bio-Rad Laboratories reported Q4 2020 results with net sales of $789.8 million, a 26.5% increase from Q4 2019. Life Science segment sales surged 77.1% to $428.5 million, largely driven by COVID-19-related demand. Gross margin improved to 58.3% from 52.9% year-over-year. Net income soared to $839.1 million, or $27.81 per share, compared to $553.5 million, or $18.31 per share in Q4 2019. Clinical Diagnostics segment saw a 5.1% decrease in sales. The company was awarded Emergency Use Authorization for new COVID-19 tests.
FAQ
What is the current stock price of Bio-Rad Laboratories (BIO)?
What is the market cap of Bio-Rad Laboratories (BIO)?
What does Bio-Rad Laboratories, Inc. specialize in?
When was Bio-Rad Laboratories founded?
Where is Bio-Rad Laboratories headquartered?
What are the core business segments of Bio-Rad?
What percentage of Bio-Rad's sales come from the Clinical Diagnostics segment?
How many employees does Bio-Rad have?
What is Bio-Rad's involvement in the biopharmaceutical industry?
What is Bio-Rad's market reach?
What is the significance of Bio-Rad's ownership in Sartorius?
How does Bio-Rad contribute to scientific research and development?
